Veterans with vision loss may get new rehab tools
NCT ID NCT05780931
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to develop new methods to help veterans with vision loss caused by age-related macular degeneration. About 20 veterans aged 50 and older with reduced vision will take part. Researchers will measure how well they recognize objects and how their brains respond before, during, and after the rehab procedures.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 20 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Aug 2026
An estimate. Start dates often move.
- Expected to finish
-
May 2027
An estimate. End dates often move.
- Lead sponsor
-
A government agency
The lead sponsor is a US federal agency other than the NIH.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Veterans with vision loss caused by age-related macular degeneratioin
- Ages
-
50 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. The subject is a Veteran. 2. The subject is 50 years of age. 3. The subject has best-corrected visual acuity (BCVA) of 20/40 or worse in each eye, as determined by the standard CNVAMC optometric tests. 4. The subject has visual field deficit of 10O in either eye as determined by the Octopus 900 perimetry (Haag-Streit Diagnostics, Haag-Streit USA, Mason, OH) administered by CNVAMC. (When the deficit/s are binocular, they do not necessarily have to be in binocularly corresponding positions.) 5. The subject has received a formal clinical diagnosis of age-related macular degeneration (AMD) in one or both eyes (binocular AMD does not necessarily have to be in binocularly corresponding positions)7,8,56. 6. The subject has visual deficit in either eye (wavy lines and/or missing/darkened areas on the grid) determined by the standard Amsler Grid Test7,8,56. 7. The subject has not yet started any rehabilitative treatment for AMD-related vision loss. 8. Both eyes of the subject are otherwise age-appropriately stable, and neither eye has any other visual defects, as determined by the standard CNVAMC ophthalmological examination. 9. The subject must be able to understand the nature and individual consequences of the study. 10. The subject must be able to provide signed and dated informed consent before start of any participation in the study procedures. 11. Women with childbearing potential must test negative for pregnancy using a standard urine test prior to participating in each functional magnetic resonance imaging (fMRI) procedure. (This exclusion criterion is mandated by the Augusta University Institutional Review Board \[AU IRB\], which also serves as the IRB of record of the CNVAMC. It is intended as an extra precautionary measure to help ensure the health and safety of this vulnerable population. The proposed study will comply with this requirement.) Exclusion Criteria: 1. According to the patient's VA clinical records, the patient has one or more clinically diagnosed neurological disorder. 2. According to the patient's VA clinical records, the patient has one or more clinically diagnosed cognitive deficits. 3. According to the patient's VA clinical records, the patient has been clinically diagnosed with a psychiatric disorder that would make it unduly uncomfortable or otherwise clinically inadvisable for the subject to participate in the study. 4. According to the patient's VA clinical records, according to the patient, or both, the patient has motor disorder/s that would make it unduly uncomfortable or otherwise clinically inadvisable for the subject to participate in the study. 5. According to the patient's VA clinical records, according to the patient, or both, the patient has an MR-incompatible implant and/or another condition (e.g., claustrophobia) that would make it inadvisable for the subject to participate in MR imaging or any other study procedure. 6. The patient does not understand the informed consent information and/or the standard study instructions in spoken or written English, and/or is unable to follow study instructions. \[The purpose of this exclusion criterion, required by the AU IRB, is to help ensure that the subjects adequately understand all the information relevant to providing informed consent, as well as the study instructions.\] 7. Inability to give informed consent to participate in the study. 8. Pregnancy, as determined by a standard urine test for pregnancy. 9. Participation in other study/studies including an investigational drug or device during the present study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Age-related macular degeneration (AMD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Charlie Norwood VA Medical Center, Augusta, GA
Augusta, Georgia, 30904-6258, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can At-Home eye scans personalize wet AMD treatment?
- AI eye doctor: could a computer spot Blindness-Causing diseases faster than humans?
- Gene therapy injection aims to halt blinding eye disease
- Scientists track Long-Term safety of experimental AMD therapy
- AMD Patients' knowledge gaps revealed in new study
- Cheaper eye drug could save millions in AMD treatment costs